Retatrutide, developed by Soma Corp., is attracting considerable attention as a potential treatment for weight control . This dual-action compound combines the activity of a GLP-1 receptor activator and a GIP receptor agonist , intended to simply promote weight loss but also improve associated metabolic factors. Early human trials have indicated en